Quantum Genomics Corp. (Nyse Euronext Paris: MLQGC) Announced Today Positive Scientific Results With Its Product QGC001

MASSY, FRANCE--(Marketwire - April 01, 2011) -

Quantum Genomics (NYSE Euronext Paris: MLQGC) announced today excellent results from regulatory preclinical studies conducted with the product QGC001, the first drug-candidate of a new class of central anti-hypertensive agents, brain aminopeptidase A inhibitors (BAPAI):

  * Anti-hypertensive activity of QGC001 after oral administration has been
    demonstrated in spontaneously hypertensive rats and conscious
    hypertensive DOCA-salt rats
  * Toxicology, safety pharmacology and pharmacokinetics studies have
    demonstrated that QGC001 is well tolerated both in rats and dogs at
    doses superior to 50 times the dose showing anti-hypertensive activity
    in rats and has a good bioavailability in dog.

Quantum Genomics plans to submit to AFSSAPS in the following weeks, a clinical trial application in order to initiate a single ascending dose (SAD) study in healthy male volunteer subjects and assess the tolerability of a single dose of QGC001 and its pharmacokinetics parameters in humans.

"Thanks to our academic partners and the financial support of our shareholders, Oseo and the National Research Agency (ANR), we completed successfully all the preclinical studies required for the Investigational Medicinal Product Dossier. We are very confident for the further clinical development of our leading compound QGC001 based on the excellent results obtained so far" said Lionel Ségard, President and Chief Executive Officer of Quantum Genomics.

About Quantum Genomics.

QGC is a biotechnology company seeking to develop new therapies in areas where an unmet medical need exists. QGC is presently focused on the treatment of hypertension.

It will co-develop those products with academic teams and will set up strategic alliances and commercial partnerships with larger company in order to make it to market. Quantum Genomics owns the worldwide exclusive license from Inserm for QGC 001. The company is headquartered in Massy France under the leadership of Lionel Ségard, supported by a management team of experienced people, including Fabrice Balavoine (VP Research & Development) and Michel Lepers (VP Business Development)

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Quantum Genomics via Thomson Reuters ONE

[HUG#1502645]